ARAY
Accuray IncOne customer — 17% of revenue (the three months ended March 31, 2026)
“The JV represented approximately 17% and 21% of our total net revenue during the three months ended March 31, 2026 and 2025 respectively”
One customer — 16% of revenue (the nine months ended March 31, 2026)
“and represented approximately 16% and 27% of our total net revenue during the nine months ended March 31, 2026 and 2025 respectively.”
One customer — 13% of receivables (As of March 31, 2026)
“As of March 31, 2026, and June 30, 2025, the JV represented approximately 13% and 33%, respectively, of our total accounts receivable balance.”
Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$1.9M | Q2 FY2026 | — |
| Book to bill ratio | 1.5 | Q2 FY2026 | — |
| Gross product orders | $66.1M | Q2 FY2026 | — |
| Order backlog | $383.3M | as of December 31, 2025 | — |
| Restructuring charges | $6.1M | Q2 FY2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARAY
this stock
Accuray Inc
|
$28.71M | -70.7% | +3.9% | — | 4.1% |
|
ABT
Abbott Laboratories
|
$163.61B | -24.7% | +5.7% | 26.3 | 1.3% |
|
SYK
Stryker Corp
|
$126.42B | -5.9% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$107.36B | -12.0% | +8.4% | 22.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.54B | -53.0% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARAY | -4.0% | -27.3% | -72.4% | -7.7% | -70.7% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -5.4% | -31.3% | -81.5% | -8.8% | -81.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.